Dyne Therapeutics, Inc. (DYN) has 16 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 15 sales totalling $113.8M. Most recent filing: Sept. 8, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 8, 2026 filed Sept. 4, 2026 | Friedl-Naderer Johanna Chief Commercial Officer | −$25,408 | 1,085 | −1% | Yes | |
|
|
||||||
| Sept. 8, 2026 | Cox John CEO & President | −$106,823 | 5,658 | −2% | Yes | |
|
|
||||||
| Sept. 8, 2026 filed Sept. 4, 2026 | Kerr Douglas Chief Medical Officer | −$115,546 | 5,035 | −3% | Yes | |
|
|
||||||
| Aug. 17, 2026 filed Aug. 13, 2026 | Rhodes Jason P Director | −$65,184,894 | 2,586,928 | −86% | Yes | |
|
|
||||||
| Aug. 17, 2026 filed Aug. 13, 2026 | Friedl-Naderer Johanna Chief Commercial Officer | −$5,939 | 226 | −0% | Yes | |
|
|
||||||
Showing the 5 most recent of 16 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free